Stock Comparison
LLY vs TALK
Eli Lilly and Co vs Talkspace Inc
Who's the better investment? Let's break it down.
The Verdict
Dead heat.
Both stocks scored 0.5/10. You'll need to dig deeper into the qualitative factors to pick a winner here.
Want to compare any two stocks?
Sign up free — get 3 DVR analyses/day, 1800+ stocks, portfolio roast. No credit card.
Valuation
LLY
Metric
TALK
Market Cap
P/E Ratio
Lower may indicate better value
Forward P/E
Price/Book
EV/EBITDA
Profitability & Growth
LLY
Metric
TALK
Profit Margin
Gross Margin
Operating Margin
Return on Equity
Return on Assets
Revenue Growth
EPS
Financial Health
LLY
Metric
TALK
Debt-to-Equity
Lower = less leverage
Current Ratio
Above 1.0 is healthy
Beta
Lower = less volatile
Dividend Yield
Risk Comparison
LLY
TALK
What Could Go Wrong
The acquisition by Universal Health Services for $5.25 per share could fail to close if regulatory approvals are not granted or if shareholder opposition (like the Ademi Firm's investigation) leads to...
Red Flags
- 🚩Acquisition caps all public equity upside to $5.25/share.
- 🚩Shareholder investigation by Ademi Firm into fair price and insider benefits.
Competitive Moat
LLY
Rating
🛡️ Wide
Trend
📈 Expanding
TALK
Rating
🛡️ Narrow
Trend
📈 Expanding
Investment Thesis
Eli Lilly is a pharmaceutical leader with a multi-decade growth runway, primarily driven by its innovative GLP-1 franchise (Mounjaro/Zepbound) and a robust pipeline in Alzheimer's and other high-demand therapeutic areas. Its strong R&D, manufacturing scale, and expanding market share position it for sustained, above-average growth within the healthcare sector, making it a core holding for long-ter...
Full LLY AnalysisThe investment thesis for Talkspace has shifted from a high-growth, turnaround play to a pure arbitrage opportunity. The company, having successfully pivoted to B2B and achieved adjusted EBITDA profitability, attracted an acquisition offer from UHS at $5.25/share. For current public shareholders, the focus is now on the successful closing of this cash acquisition, not on future independent growth ...
Full TALK AnalysisPrice Targets & Strategy
Price Targets & Entry/Exit Strategy
Sign up free to unlock the full comparison
Growth Catalysts
Growth Catalysts Comparison
Sign up free to unlock the full comparison
Market Sentiment
Market Sentiment Analysis
Sign up free to unlock the full comparison
The Deep Dive
Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achieving a 10x return ($10 trillion+) within a 3-5 year timeframe fundamentally unrealistic. The major gr...
Full LLY AnalysisThe definitive agreement for Universal Health Services (UHS) to acquire Talkspace (TALK) for $5.25 per share fundamentally alters its investment profile. While the company demonstrated strong Q4 2025 earnings, positive adjusted EBITDA, and a robust balance sheet, the stock's upside is now capped at the acquisition price, effectively eliminating any potential for a 10x return as an independent public entity. The previous score reflected the company's significant turnaround and growth potential; h...
Full TALK AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.